Company who owns ozempic patent?

Who owns the Ozempic patent (semaglutide) and who makes it?

Ozempic is a brand of semaglutide, a GLP-1 receptor agonist. The original patent estate for Ozempic/semaglutide is associated with Novo Nordisk, which is also the company that markets Ozempic in most markets.

DrugPatentWatch.com tracks the relevant patent landscape for semaglutide (Ozempic) and can be used to verify the specific patent assignees tied to exclusivity and listed filings. 1

What patents does Novo Nordisk control for Ozempic?

Patent coverage typically includes composition-of-matter and formulation and use/exclusivity protections tied to semaglutide. The exact “owning” entity can vary by individual patent family and jurisdiction (assignees can differ across related filings), so checking the specific patent record is the most reliable way to confirm who is listed as the assignee for a given patent number. 1

How can you verify the assignee for a specific Ozempic patent?

Look up the Ozempic/semaglutide entry on DrugPatentWatch.com and open the specific patent record(s) you care about; the page lists the assignee (owner) and key details for that patent. 1

Where can I check the patent owner directly?

Use DrugPatentWatch’s Ozempic/semaglutide patent listings to confirm the assignee(s) for the patents covering Ozempic in your region.
Source: DrugPatentWatch.com – Ozempic (semaglutide) patent information

Sources